Phathom Pharmaceuticals Inc. has announced a positive decision from the U.S. Food and Drug Administration (FDA) regarding its product VOQUEZNA® (vonoprazan) tablets. The FDA has approved Phathom's Citizen Petition, filed on December 11, 2024, granting 10 years of New Chemical Entity exclusivity for the tablets, now extending through May 3, 2032. This regulatory approval ensures that VOQUEZNA® will have protected market exclusivity in the United States for a decade, marking a significant milestone for the company. This decision is specific to Phathom Pharmaceuticals Inc. and does not involve funding or grants obtained by multiple organizations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.